Cases & Deals

  • Home
  • Practices
  • TxCell implements two-year equity line with Société Générale

Share

TxCell implements two-year equity line with Société Générale

January 2016

Client(s) TxCell SA

Jones Day advised TxCell SA, a biotech company specializing in innovative, personalized cell-based immunotherapies, in connection with the implementation of a two-year equity line with Société Générale.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.